



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

0 223 403 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(46) Date of publication of patent specification: 04.08.93 (51) Int. Cl.5: C07D 405/12, C07D 211/22, A61K 31/445  
(21) Application number: 86307919.0  
(22) Date of filing: 14.10.86

The file contains technical information submitted after the application was filed and not included in this specification

(54) Piperidine derivative, Its preparation, and its use as medicament.

(30) Priority: 25.10.85 GB 8526407  
25.10.85 GB 8526408  
(43) Date of publication of application:  
27.05.87 Bulletin 87/22  
(45) Publication of the grant of the patent:  
04.08.93 Bulletin 93/31  
(54) Designated Contracting States:  
BE CH DE ES FR GB GR IT LI LU NL SE  
(66) References cited:  
EP-A- 0 190 496  
US-A- 4 007 196

CHEMICAL ABSTRACTS, vol. 92, no. 7, February 18, 1980, page 28 abstract-no. 51771j, Columbus, Ohio, US; E.N. PETERSEN et al.: "5-HT antagonism on cerebral and common carotid arteries by the 5-HT uptake Inhibitors femoxetine and paroxetine"

(73) Proprietor: BEECHAM GROUP PLC  
Beecham House Great West Road  
Brentford Middlesex TW8 9BD(GB)  
(72) Inventor: Barnes, Roger Duncan, c/o Beecham Pharmaceuticals  
Brockham Park  
Batchworth, Surrey RH3 7AJ(GB)  
Inventor: Wood-Kaczmar, Marlan Wladylaw  
c/o Beecham Pharmaceuticals, Coldharbour  
Road  
The Pinnacles, Harlow, Essex CM19 5AD(GB)  
Inventor: Richardson, John Edward  
c/o Beecham Pharmaceuticals, Coldharbour  
Road  
The Pinnacles, Harlow, Essex CM19 5AD(GB)  
Inventor: Lynch, Ian Robert, c/o Beecham  
Pharmaceuticals  
Great Burgh, Yew Tree Bottom Road  
Epsom, Surrey KT18 5XQ(GB)  
Inventor: Buxton, Phillip Christopher, c/o Beecham  
Pharmaceuticals  
Great Burgh, Yew Tree Bottom Road  
Epsom, Surrey KT18 5XQ(GB)

BEST AVAILABLE COPY

EP 0 223 403 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**CHEMICAL ABSTRACTS**, vol. 95, no. 7, August 17, 1981, page 22, abstract-no. 54664z, Columbus, Ohio, US; M. GOERTHERT et al.: "Alpha-adrenoceptor-mediated modulation of 5-hydroxytryptamine release from rat brain cortex slices"

Inventor: Curzons, Alan David, Beecham Pharmaceuticals  
Clarendon Road  
Worthing, West Sussex BN14 8QH(GB)

⑦ Representative: Lockwood, Barbara Ann et al.  
Beecham Pharmaceuticals Biosciences Research Centre Great Burgh Yew Tree Bottom Road  
Epsom Surrey KT18 5XQ (GB)

## Description


This invention relates to crystalline paroxetine hydrochloride, its preparation and its use as a therapeutic agent.

5 US Patent 4007196 discloses a class of compounds that are inhibitors of 5-hydroxytryptamine (5HT) uptake and thus of therapeutic use as anti-depressants. In Example 2 of the US patent there is described the preparation of (-)-trans-4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxy)methyl)-piperidine of formula A:

10

15

20



25 In this specification the compound of formula A is referred to by its generic name of paroxetine.

Because of its basicity, it is preferred that paroxetine is used as a therapeutic agent in the form of an acid addition salt. In Example 2 of US Patent 4007196, paroxetine is obtained as the free base and then converted to its maleic acid salt.

30 The acetate salt of paroxetine has been used in most of the published experimental trials [for example, *Psychopharmacology*, 57, 151-153 (1978); *ibid.* 68, 229-233 (1980); and *European Journal of Pharmacology*, 47 (1978) 351-358]. There has also been limited use of the hydrochloride salt (in aqueous solution) [*Acta Pharmacol. et Toxicol.* 1979, 44, 289-295]. However, the preparation of paroxetine hydrochloride has not been described in the literature.

35 In general, the hydrochloride salt of a basic compound is preferred for therapeutic use because of its physiological acceptability.

However for commercial use, it is also important that the solid product should have good handling qualities.

We have found that amorphous paroxetine hydrochloride is a hygroscopic solid of poor handling qualities.

40 It has now been discovered that paroxetine hydrochloride can be produced in crystalline form in a manner reproducible on a commercial scale.

The present invention provides crystalline paroxetine hydrochloride hemihydrate as a novel material, in particular in pharmaceutically acceptable form.

45 Paroxetine hydrochloride hemihydrate normally has a melting point in the range of 128 - 132 °C, preferably 129 - 131 °C. It is stable and non-hygroscopic. It is characterized by an X-ray powder diffractogram as shown in the accompanying drawing (Fig.1). A typical Nujol infra-red spectrum (Fig.2) and DSC profile (prepared using a 2.26 mg sample in a sealed container (Fig.3) is also shown. Under extreme dessication conditions the bound water may be removed to give an anhydrous form, but on rehydration it rapidly reforms the hemihydrate.

50 The present invention also provides a process for producing crystalline paroxetine hydrochloride hemihydrate which comprises forming a solution of paroxetine hydrochloride and precipitating the crystalline form from solution.

The solution may be formed by dissolution of pre-formed paroxetine hydrochloride or by forming the hydrochloride in situ. The hydrochloride may be formed from a solution of paroxetine free base or a salt other than the hydrochloride by contacting it with hydrogen chloride.

55 For example a solution of hydrogen chloride, for example concentrated hydrochloric acid or an organic solvent saturated with hydrogen chloride may be added to a solution of paroxetine salt. Alternatively hydrogen chloride gas may be passed through the paroxetine (salt) solution.

Paroxetine base may be prepared by the procedure disclosed in US Patent 4007196. The US Patent also gives procedures for preparing salts of paroxetine with various organic acids.

Typically, paroxetine hydrochloride may be obtained from an organic solution e.g. in toluene, of the free base by adding an appropriate amount of aqueous HCl.

5 In a procedure using a salt, paroxetine hydrochloride may be produced from a paroxetine C<sub>1</sub>-carboxylate such as the acetate. The acetate may be obtained by reaction of acetic acid and paroxetine base in a non-polar solvent, such as diethyl ether or isopropyl ether. Alternatively it may be obtained from an aqueous solution obtained by extraction from a water-immiscible solvent e.g. toluene, ethyl acetate, by the addition of water and an appropriate amount of acetic acid.

10 Before conversion to the hydrochloride or crystallisation it may be desirable to remove impurities, since it has been found that some impurities may act as crystallisation inhibitors. However, the hemihydrate can even be obtained from relatively impure starting material, by means of seeding.

15 Paroxetine hydrochloride may be obtained as a crystalline hemihydrate by crystallisation after addition of an aqueous solution of hydrochloric acid to a solution of paroxetine free base in water immiscible solvents e.g. toluene, or by crystallisation from water-miscible solvents which do not form a solvate (e.g. IMS) after adding aqueous hydrochloric acid to a solution of the free base or by crystallising or recrystallising paroxetine hydrochloride from a solvent system containing water e.g. IMS/water. Alternatively the hydrochloride hemihydrate can be produced via another paroxetine salt by the addition of hydrochloric acid to an aqueous solution of the salt e.g. acetate.

20 In a preferred aspect, this invention provides paroxetine hydrochloride hemihydrate which is substantially pure.

The hemihydrate can be obtained by crystallisation from a range of solvents, although seeding may be necessary in some instances, after addition of aqueous HCl to a solution of the free base or another salt. Solvents which have been found suitable are toluene, water, IMS, lower alcohols such as ethanol and isopropanol and ethyl acetate. The same solvent range may be used for recrystallisation.

25 In a particular aspect of the invention, paroxetine free base is synthesised in a particularly pure form which is especially suitable for use in the preparation of the crystalline paroxetine hydrochloride hemihydrate of the invention, even without seeding.

In the above mentioned U.S. Patent 4007196, for the preparation of paroxetine (Examples 1 and 2), an 30 N-methyl compound is reacted with phenyl chloroformate and the resultant compound is hydrolysed with potassium hydroxide.

One disadvantage of this process is that the solvent used during the hydrolysis step (methyl cellosolve) leads to the production of unwanted transesterification by-products.

35 We have now discovered that the purity of the final product can be improved by using a different solvent during the hydrolysis step, such as toluene. A further advantage is that the temperature at which the hydrolysis is carried out can thus be reduced, owing to the reduction in boiling point of the solvent used.

The pure paroxetine free base thus obtained can then be used for the preparation of crystalline paroxetine hydrochloride hemihydrate as set out above.

40 In a further aspect of the invention, crystalline paroxetine hydrochloride hemihydrate can be obtained by compressing crystalline paroxetine hydrochloride anhydride.

In a still further particular aspect of the invention, paroxetine is synthesised directly as its hydrochloride salt, followed by crystallisation as set out above.

45 We have discovered a new process for the preparation of paroxetine and related compounds by a deacylation procedure which advantageously provides the desirable hydrochloride salt directly.


45

50

55

Accordingly, the present invention provides a process for the preparation of a compound of formula I

5



10


15

in which  $R^2$  represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by  $C_{1-4}$  alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl, and  $X$  represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio, or aralkyloxy, by de-acylating a compound of formula II

25

30


35



45

60

55



in which  $R^3$  is an alkyl group.

The replacement of  $R^3$  by  $R^1\text{CHClO.CO}$  to convert the compound of formula III to the compound of formula II may be achieved by reacting the compound of formula III with  $\alpha$ -chloro-ethyl chloroformate in a


solvent such as dichloroethane or toluene.

Alternatively, the compound of formula III may be reacted with vinyl chloroformate in a solvent such as methylene dichloride or toluene to obtain the intermediate of formula IV

5

10

15



IV

which is then treated with HCl, preferably by passing HCl gas through the solution to obtain the compound of formula II.

An advantageous feature of this process is that the conversion of the compound of formula III into the compound of formula I can be carried out as a 'one-pot' process without isolating the intermediate of formula II or the intermediate of formula IV if the alternative route is followed.

The compounds of formula III may be prepared by the procedures set out in US 4007196.

Advantageously, the process is used for the de-alkylation of a compound of formula IIIa to obtain paroxetine hydrochloride of formula Ia. This procedure is illustrated in the following reaction scheme.

30


35

40

45

50

55



The present invention provides paroxetine hydrochloride hemihydrate in pharmaceutically acceptable form.

The present invention also provides a pharmaceutical composition comprising crystalline paroxetine hydrochloride hemihydrate and a pharmaceutically acceptable carrier.

The compositions of this invention are usually adapted for oral administration, but formulations for dissolution for parenteral administration are also within the scope of this invention.

The composition is usually presented as a unit dose composition containing from 1 to 200 mg, more usually from 5 to 100 mg, for example 10 to 50 mg such as 12.5, 15, 20, 25 or 30 mg. Such composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400 mg.

Preferred unit dosage forms include tablets or capsules.

The composition of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.

Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or a preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for clinically used anti-depressant agents.

The invention also provides a method of treatment of depression in mammals including humans which method comprises administering an effective amount of pharmaceutically acceptable crystalline paroxetine hydrochloride hemihydrate.

The invention further provides pharmaceutically acceptable crystalline paroxetine hydrochloride hemihydrate for use in the treatment of depression.

The following Examples illustrate the invention. Examples 4 and 5 show the route formula III-IV-II-I, whilst Examples 6 and 7 show the route formula III-II-I. Temperatures are in °C.

Example 1

5 (-)-Trans-4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxy)methyl)piperidine hydrochloride (Paroxetine hydrochloride) as hemihydrate ( $\frac{1}{2}\text{H}_2\text{O}$ )

(-)-Trans-4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxy)methyl)-N-phenoxy carbonylpiperidine

10 (18.5gms) was dissolved in toluene(275mls). Potassium hydroxide (15.7gms) was added. The mixture was refluxed for 2 hours with good agitation. The slurry was then cooled to 20 °C and the toluene washed once with water (275mls).

To a solution of 13.5g Paroxetine free base in toluene(300ml) was added a small excess of either concentrated hydrochloric acid(5.2ml) or dilute hydrochloric acid (150mls of 0.35N)

15 The slurry was stirred at ambient temperature for 2 hours. The product was washed with toluene/water(25ml 1:1 mixture) and dried at 50 °C to give paroxetine hydrochloride as the hemihydrate ( $\frac{1}{2}\text{H}_2\text{O}$ ) containing 2.5%  $\text{H}_2\text{O}$  with m.p. 128 - 133 °C, and IR consistent with authentic material.

Example 2

20 (-)-Trans-4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxy)methyl)piperidine hydrochloride (Paroxetine hydrochloride) as hemihydrate ( $\frac{1}{2}\text{H}_2\text{O}$ )

To a solution of paroxetine free base obtained as described in Example 1 [23.5g] in toluene (ca.500ml) was added 300ml water. Acetic acid was added (6.4g) and after 15 minutes stirring the lower aqueous layer containing paroxetine acetate was separated.

The aqueous layer was clarified by filtration through celite. Concentrated hydrochloric acid (15.0ml) was then added at ambient temperatures in the presence of paroxetine hydrochloride seed obtained as in Example 1 and the precipitated product stirred for 1 hour at ambient and then 2 hours at 0-5 °C.

30 The product was filtered, washed with water (2x40ml) and dried at 50 °C to give paroxetine hydrochloride hemihydrate containing 2.6%  $\text{H}_2\text{O}$  and consistent IR.

Example 3

35 Recrystallisation of Paroxetine hydrochloride to give the hemihydrate

(a) 0.50g Paroxetine hydrochloride was recrystallised from 2.5ml IMS (industrial methylated spirit) by dissolving at ca 60 - 70 °C and cooling slowly to 20 °C then to 5 °C. After seeding with crystals obtained as in Example 1, crystals of paroxetine hydrochloride hemihydrate were deposited and isolated in the normal way.

40 (b) 0.75g Paroxetine hydrochloride was recrystallised from 5.0ml water by dissolving at ca. 70 °C and cooling slowly to 20 °C. After seeding with crystals obtained as in Example 1, crystals of paroxetine hydrochloride hemihydrate were deposited and isolated in the normal way.


45 Example 4

(-)-trans-4-(4'-Fluorophenyl)-3-(3',4'-methylenedioxyphenoxy)methyl)piperidine hydrochloride

Vinyl chloroformate (6.42ml) was dissolved in 2ml dry methylene dichloride. The solution was cooled to 0 °C and the reaction flask purged with nitrogen. A solution of (-)-trans-4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxy)methyl-N-methyl- piperidine (20g) in 52ml of dry methylene dichloride was added to the vinyl chloroformate solution over 30 minutes keeping the temperature below 0 °C. The mixture was allowed to warm to ambient temperature and stirred for 3 hours. The solution was then heated to reflux at 35 °C for a further 1 hour and cooled to -20 °C. Dry hydrogen chloride gas was bubbled into the solution for about 1 hour and the mixture allowed to stir at ambient temperature for 1 hour. Methanol (50ml) was added to the solution and the mixture heated under reflux for 1 hour, followed by addition of charcoal (4.5g) to the hot solution. Charcoal was filtered off after 10 minutes and the solvents removed in vacuo to give the crude product (21.4g). The solid was dissolved in isopropyl alcohol (140ml) and the solution filtered. The clear

filtrate was cooled to 0° and seeded with crystals obtained as in Example 1 to allow the product to crystallise. After several hours at 0° the white solid was filtered off and the product slurried in water (30ml), filtered off, washed with water and dried to give the hydrochloride salt as the hemihydrate (15.8g, 74.1%).

5. <sup>1</sup>H-n.m.r. (270 MHz, DMSO-d<sub>6</sub>)



	<u>δ</u>	<u>Multiplicity</u>	<u>Assignment</u>
25	9.50	s, br, exch.	NH <sub>2</sub> <sup>+</sup> 2H
	7.27	dd, <sup>4</sup> J <sub>HF</sub> =6Hz	2' 2H
	7.17	dd, <sup>3</sup> J <sub>HF</sub> =9Hz	3' 2H
30	6.75	d	5' 1H
	6.50	d	2'' 1H
	6.20	dd	6'' 1H
	5.94	s	O-CH <sub>2</sub> -O 2H
	3.61	dd)	7 2H
	3.53	dd)	
35	3.50	m	2 eq 1H
	3.39	d, br	6 eq 1H
	3.03	ddd	6 ax 1H
	2.97	dd	2 ax 1H
	2.90	ddd	4 1H
	2.58	m	3 1H
40	2.10	ddd	5 ax 1H
	1.85	d, br	5 eq 1H
50			

Example 5

55 (-)-trans-4-(4'-Fluorophenyl)-3-(3',4'-methylenedioxyphenoxy)methylpiperidine hydrochloride

The reaction described in Example 4 was repeated substituting 100ml of sodium dried toluene for 52 ml of dry methylene chloride. (-)-trans-4-(4'-Fluorophenyl)-3-(3',4'-methylenedioxyphenoxy)methyl-N-methyl-

5-piperidine (20g) was converted to 16.5g of the hydrochloride salt as the hemihydrate in a yield of 77.4%.  
 The  $^1\text{H-n.m.r.}$  spectrum was identical to that of the Example 4 product.

Example 6

(-)-trans-4-(4'-Fluorophenyl)-3-(3',4'-methylenedioxophenoxy)methylpiperidine hydrochloride

10 (-)-trans-4-(4'-Fluorophenyl)-3-(3',4'-methylenedioxophenoxy)methyl-N-methylpiperidine (10g) and N,N,N',N'-tetramethyl-1,8-naphthalenediamine (0.3g) were dissolved in 40ml of dry 1,2-dichloroethane (EDC) and the solution cooled to  $-3^\circ\text{C}$ .  $\alpha$ -Chloroethyl chloroformate (3.22ml) in 5ml of dry EDC was added to the cold solution over 15 minutes. The mixture was stirred for 20 hours at ambient temperature and then heated to reflux for 2 hours. Methanol (15ml) was added to the solution and the mixture was refluxed for a further 2 hours. The mixture was washed with 20ml of 1N hydrochloric acid and the phases were allowed to separate. The organic layer was evaporated to dryness and the residue was dissolved in isopropyl alcohol (60ml).  
 15 The hot solution was treated with charcoal (2g) and alumina (1.5g), stirred for 5 minutes and filtered hot. The clear solution was seeded with crystals obtained as in Example 1 and cooled to  $0^\circ\text{C}$  for 18 hours. The white crystalline solid was filtered off and the wet product slurried in water (20ml). The solid was filtered off, washed with water and dried to give the hydrochloride salt as the hemihydrate (7.9g, 74.1%).

20 The  $^1\text{H-n.m.r.}$  spectrum was the same as that of the Example 4 product.

Example 7

(-)-trans-4-(4'-Fluorophenyl)-3-(3',4'-methylenedioxophenoxy)methyl-piperidine hydrochloride

25 (-)-trans-4-(4'-Fluorophenyl)-3-(3',4'-methylenedioxophenoxy)methyl-N-methylpiperidine (10g) was dissolved in 45 ml of sodium dried toluene and the solution cooled to  $5^\circ\text{C}$ .  $\alpha$ -Chloroethyl chloroformate (3.22ml) in 5ml of dry toluene was added to the cold solution over 15 minutes. The mixture was stirred for 18 hours and methanol (15ml) was added to the mixture. The solution was stirred for 12 hours at ambient temperature. The solvent was then distilled off in *vacuo* and the residue dissolved in hot isopropyl alcohol (60ml).  
 30 The hot solution was treated with charcoal (2g) and alumina (1.5g), stirred for 5 minutes, filtered, seeded with crystals obtained as in Example 1 and cooled to  $0^\circ\text{C}$  for 18 hours. The white crystalline solid was filtered off, washed with a little isopropyl alcohol and the solid slurried in water (20ml). The solid was filtered off, washed with water and dried to give the hydrochloride salt as the hemihydrate (9.8g, 92%).

35 The  $^1\text{H-n.m.r.}$  spectrum was identical to that of the Example 4 product.

Example 8

(-)-Trans-4-(4'-fluorophenyl)-3-(3'4'-methylenedioxophenoxy)methyl)piperidine hydrochloride (paroxetine hydrochloride)

40 Crude (-)-trans-4-(4'-fluorophenyl)-3-(3'4'-methylenedioxophenoxy)methyl)piperidine (0.341 kg) is dissolved in diethyl ether (3.5 litres) and stirred with aluminium oxide (ca. 0.3 kg) for about 3 hours. Charcoal (15 g) and filter aid (celite, 15g) are added and the mixture filtered through a layer of aluminium oxide, the filtered solids being washed with more ether. To the combined ether solutions is added a mixture of acetic acid (66 ml) and ether whereupon the acetate of (-)-trans-4-(4'-fluorophenyl)-3-(3'4'-methylenedioxophenoxy)methyl)piperidine crystallises and is filtered off, washed with ether and dried.

45 The acetate salt is dissolved in isopropanol (2.4 litres) and treated with a mixture of concentrated hydrochloric acid (75 ml) and more isopropanol. After standing at about  $0^\circ\text{C}$  for about 16 hours, the crystals of the hydrochloride salt containing isopropanol (needles) are filtered off and dried. The salt is stirred in distilled water (0.5 litres) for about 20 minutes, filtered off and dried, giving (-)-trans-4-(4'-fluorophenyl)-3-(3'4'-methylenedioxophenoxy)methyl)piperidine hydrochloride anhydride (platelets m.p. 118  $^\circ\text{C}$ ). IR(Nujol Mull)  $\nu$  890, 1200, 1490, 3400, 3640  $\text{cm}^{-1}$ .

50 Samples of the anhydride were compressed at approximately 750  $\text{MNm}^{-2}$  and approximately 375  $\text{MNm}^{-2}$  for periods of about 2 minutes. The former underwent 45% conversion to the hemihydrate, whilst the latter remained unchanged.


55 Upon reexamining the samples after storage for several days, it was seen that the former sample had undergone complete conversion to the hemihydrate, whilst the latter sample had undergone about 50% conversion.

After a further week, the conversion of the latter sample was almost complete.

Claims

Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

5 1. Crystalline paroxetine hydrochloride hemihydrate wherein paroxetine has the following formula:



20 2. Crystalline paroxetine hydrochloride hemihydrate, having a melting point in the range of 128-132°C.


3. A pharmaceutical composition comprising crystalline paroxetine hydrochloride hemihydrate and a pharmaceutically acceptable carrier.

25 4. Use of crystalline paroxetine hydrochloride hemihydrate for the manufacture of a medicament for use in the treatment of depression.

5. A process for the preparation of crystalline paroxetine hydrochloride hemihydrate, which process comprises forming a solution of paroxetine hydrochloride and precipitating the crystalline form from solution.

30 6. A process for the preparation of crystalline paroxetine hydrochloride hemihydrate which process comprises forming a solution of paroxetine free base or a salt thereof other than the hydrochloride and thereafter contacting with hydrogen chloride.


35 7. A process for the preparation of crystalline paroxetine hydrochloride hemihydrate which process comprises deacylating a compound of formula IIa



55 55. wherein R<sup>1</sup> is an alkyl group and thereafter forming the hydrochloride salt according to claims 5 or 6.


## Claims for the following Contracting State : ES

5 1. A process for the preparation of crystalline paroxetine hydrochloride hemihydrate, which process comprises forming a solution of paroxetine hydrochloride and precipitating the crystalline form from solution, wherein paroxetine has the following formula:



20 2. A process for the preparation of crystalline paroxetine hydrochloride hemihydrate according to claim 1, which process comprises forming a solution of paroxetine free base or a salt thereof other than the hydrochloride and thereafter contacting with hydrogen chloride.

25 3. A process according to claim 1; which process comprises deacylating a compound of formula IIa



wherein R<sup>1</sup> is an alkyl group.

50 4. Use of crystalline paroxetine hydrochloride hemihydrate for the manufacture of a medicament for use in the treatment of depression.

## Patentansprüche


Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Kristallines Paroxetinhydrochlorid-Halbhydrat, wobei Paroxetin die folgende Formel hat:

5

10

15



2. Kristallines Paroxetinhydrochlorid-Halbhydrat mit einem Schmelzpunkt im Bereich von 128 - 132 °C.

20

3. Arzneimittel, enthaltend kristallines Paroxetinhydrochlorid-Halbhydrat und einen pharmazeutisch verträglichen Träger.

25

4. Verwendung des kristallinen Paroxetinhydrochlorid-Halbhydrats für die Herstellung eines Medikaments zur Verwendung bei der Behandlung von Depression.

30

5. Verfahren zur Herstellung von kristallinem Paroxetinhydrochlorid-Halbhydrat, umfassend das Herstellen einer Lösung von Paroxetinhydrochlorid und das Ausfällen der kristallinen Form aus der Lösung.

35

6. Verfahren zur Herstellung von kristallinem Paroxetin-hydrochlorid-Halbhydrat, umfassend das Herstellen einer Lösung von Paroxetin in Form der freien Base oder eines Salzes davon, das nicht das Hydrochlorid ist, und das anschließende Inkontaktbringen mit Chlorwasserstoff.

40

7. Verfahren zur Herstellung von kristallinem Paroxetinhydrochlorid-Halbhydrat, umfassend die Deacylierung einer Verbindung der Formel IIa


35

45

50

60

(IIa)




in der R<sup>1</sup> einen Alkylrest bedeutet und die anschließende Erzeugung des Hydrochloridsalzes gemäß Anspruch 5 oder 6.

55 Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zur Herstellung von kristallinem Paroxetinhydrochlorid-Halbhydrat, umfassend das Herstellen einer Lösung von Paroxetinhydrochlorid und das Ausfällen der kristallinen Form aus der Lösung, wobei

Paroxetin die folgende Formel hat:




15

2. Verfahren zur Herstellung von kristallinem Paroxetinhydrochlorid-Halbhydrat gemäß Anspruch 1, wobei das Verfahren das Herstellen einer Lösung von Paroxetin in Form der freien Base oder eines Salzes davon, welches nicht das Hydrochlorid ist, und das anschließende Inkontaktbringen mit Chlorwasserstoff umfaßt.

20

3. Verfahren nach Anspruch 1; umfassend die Deacylierung einer Verbindung der Formel IIa



in der R<sup>1</sup> einen Alkylrest bedeutet.

40

4. Verwendung von kristallinem Paroxetinhydrochlorid-Halbhydrat für die Herstellung eines Medikamente zur Verwendung bei der Behandlung von Depression.

**Revendications**

**Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

45


1. Chlorhydrate hémihydraté de paroxétine cristallin, dans lequel la paroxétine est représentée par la formule suivante :

50

55

5

10



15. 2. Chlorhydrate hémihydraté de paroxétine cristallin, ayant un point de fusion dans la gamme de 128 à 132 °C.

3. Composition pharmaceutique, comprenant du chlorhydrate hémihydraté de paroxétine cristallin et un support acceptable du point de vue pharmaceutique.

20. 4. Utilisation de chlorhydrate hémihydraté de paroxétine cristallin pour la fabrication d'un médicament utile dans le traitement de la dépression.

25. 5. Procédé pour la préparation du chlorhydrate hémihydraté de paroxétine cristallin, qui comprend la formation d'une solution de chlorhydrate de paroxétine et la précipitation de la forme cristalline à partir de la solution.

30. 6. Procédé pour la préparation du chlorhydrate hémihydraté de paroxétine cristallin, qui comprend la formation d'une solution de paroxétine sous forme de la base libre ou d'un sol de celle-ci autre que le chlorhydrate et ensuite, la mise en contact avec de l'acide chlorhydrique.


7. Procédé pour la préparation du chlorhydrate hémihydraté de paroxétine cristallin, qui comprend la désacylation d'un composé de formule IIa :

35

40

45

60




IIa

## Revendications pour l'Etat contractant suivant : ES

55


1. Procédé pour la préparation du chlorhydrate hémihydraté de paroxétine cristallin, qui comprend la formation d'une solution de chlorhydrate de paroxétine et la précipitation de la forme cristalline à partir de la solution, dans lequel la paroxétine est représentée par la formule suivante :



15 2. Procédé pour préparer du chlorhydrate hémihydraté de paroxétine cristallin suivant la revendication 1, qui comprend la formation d'une solution de paroxétine sous forme de la base libre ou d'un sel de celle-ci autre que le chlorhydrate et ensuite, la mise en contact avec de l'acide chlorhydrique.

3. Procédé suivant la revendication 1, qui comprend la désacylation d'un composé de formule IIa :

20




40 4. Utilisation de chlorhydrate hémihydraté de paroxétine cristallin pour la fabrication d'un médicament utile dans le traitement de la dépression.

45

60

55

Fig. 1







Fig. 2

Fig. 3



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**